BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25

• Press Releases

  Alzheon Announces Peer-Reviewed Publication Showing Oral Valiltramiprosate/ALZ-801 Achieves Sustained Plasma Biomarker Reductions Linked to Better Cognitive, Functional, and Brain Atrophy Outcomes in APOE4 Carriers with Early Alzheimer’s Disease

  September 8, 2026

   · 

  12 min read
• 

  Cardiovascular disease

  Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons

  The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.

  September 8, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer

  The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significantly larger opportunity” for the drug.

  September 8, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

  September 8, 2026

   · 

  11 min read
• Press Releases

  Prana Therapies Announces Positive Phase 1 Results for PRA-216, a Novel IL-4Rα/TSLP Bispecific Antibody, Supporting Its Potential Best-in-Disease Profile and Providing the First Clinical Validation of Prana’s INSPIRE Multispecific Platform

  September 8, 2026

   · 

  4 min read
• Press Releases

  UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment

  September 8, 2026

   · 

  7 min read
• Press Releases

  Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

  September 8, 2026

   · 

  3 min read
• Press Releases

  Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

  September 8, 2026

   · 

  7 min read
• Press Releases

  Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

  September 8, 2026

   · 

  8 min read
• Press Releases

  Generate Biomedicines Inc. to Participate in September 2026 Investor Conferences

  September 8, 2026

   · 

  4 min read